Replies to post #86207 on Biotech Values

[DewDiligence]

That has to be the richest deal for a single Phase I compound I have ever seen.

As part of this purchase, ABT presumably picked up PanGenetics’ IP for the anti-NGH pathway and all of the analogs of the lead drug. The deal terms are still astonishingly rich, but ABT is getting a little more than a single phase-1 compound.

[rkrw]

What's interesting is it's virtually all up front. I've never seen such a front end loaded deal. Certainly there have been phase I deals with more biobucks just usually with minimal upfronts and usually that's the last you hear of them.

[tony111]

Zymo's interferon lambda deal is the best deal for a compound in phase 1